NCT01690702View on ClinicalTrials.gov

Study of Nab-Paclitaxel in High Risk Early Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

2,886

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2018

Study Completion Date

July 20, 2020

Conditions
Breast Cancer
Interventions
DRUG

Epirubicin

DRUG

nab-Paclitaxel

DRUG

Cyclophosphamide

DRUG

Docetaxel

Trial Locations (1)

65929

Klinikum Frankfurt Höchst, Frankfurt am Main

Sponsors

Collaborators (2)

Celgene
Amgen
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

GBG Forschungs GmbH

OTHER

NCT01690702 - Study of Nab-Paclitaxel in High Risk Early Breast Cancer | Biotech Hunter | Biotech Hunter